Regeneron’s Libtayo/Fianlimab LAGs Bristol’s Opdualag On Timing, But May Win On Efficacy

While it is still early days and small patient numbers, Regeneron Pharmaceuticals, Inc.’s combination of its PD-1 inhibitor Libtayo (cemiplimab) and LAG-3 inhibitor fianlimab showed an overall response rate (ORR) and median progression-free survival (PFS) in patients with advanced melanoma that so far looks favorable compared with Bristol Myers Squibb Company’s approved PD-1/LAG-3 combination, Opdualag (nivolumab and relatlimab-rmbw), especially in patients with prior adjuvant PD-1 therapy.

The Tarrytown, NY-based company presented data from its Phase I study for the combination at the American Society of